For patients with hepatocellular carcinoma treated in the second-line setting, the combination of regorafenib and nivolumab following 2 cycles of regorafenib monotherapy appeared safe, according to phase 1/2a study.
Treatment with atezolizumab plus bevacizumab in the first-line setting achieved better responses for patients with unrespectable hepatocellular carcinoma when their disease had a viral versus nonviral etiology and neutrophil-to-lymphocyte ratio was less than 3.6.
Findings from the INSEMA study show that patients who received either sentinel lymph node biopsy or complete axillary lymph node dissection experienced differences in breast and arm symptoms compared with patients who did not.
Patients with late- and early-relapsed multiple myeloma receiving the combination of selinexor plus daratumumab, bortezomib, and dexamethasone showed promising efficacy and a manageable safety profile.
Frontline ibrutinib and rituximab plus fludarabine, cyclophosphamide, and rituximab improved quality of life in patients with chronic lymphocytic leukemia; ibrutinib given continuously maintained the improved quality of life, and it did not decline over time.